It’s just another earnings week in the life of pharmaceutical CEOs, with blockbuster expectations running up against cruel reality.
Data from two promising vaccine trials heralded potential breakthroughs in the treatment of pneumococcal infection and Lyme disease.
Moderna says it was willing to licence the tech but now wants to be repaid by rivals for vaccine revenue generated since then.
For the first time in exactly 10 years, Wall Street dealmakers will fall short of facilitating at least $3 trillion worth of deals.
Pfizer’s stock slumped its lowest level in more than 10 years. The world’s moved on from the pandemic, and nobody loves you when you’re down.
Roche agreed Monday to acquire anti-obesity drug developer Carmot Therapeutics for an appetizing $3.1 billion.
Moderna posted a quarterly loss of $3.63 billion, half of which was accounted for by unused Covid-19 shots past their expiration date.
The weight loss drug market could be worth $100 billion in the next few years. Naturally, other companies want in.